Vesicular monoamine transporter 2: role as a novel target for drug development
about
Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistryFunctional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humansTetrabenazine: Spotlight on Drug Review.The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in ratsExperimenting with spirituality: analyzing The God Gene in a nonmajors laboratory courseIn Vitro and In Vivo Characterization of the Alkaloid NuciferineCatecholamines up integrates dopamine synthesis and synaptic traffickingReward processing in autism: a thematic series.Effect of high-fat feeding on expression of genes controlling availability of dopamine in mouse hypothalamusDesign, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.Preparation and Characterization of Tetrabenazine Enantiomers against Vesicular Monoamine Transporter 2.New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2)Synthesis of H-Labeled Tetrabenazine (TBZ)The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.Brain dopamine and serotonin differ in regulation and its consequencesSynthesis of (±)-Tetrabenazine by Visible Light Photoredox CatalysisAntiepileptic activity of lobeline isolated from the leaf of Lobelia nicotianaefolia and its effect on brain GABA level in miceLobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters.Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivoTetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's diseaseSex differences in tolerance to the locomotor depressant effects of lobeline in periadolescent rats.N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.Dopamine D2 receptor relies upon PPM/PP2C protein phosphatases to dephosphorylate huntingtin proteinMonoamine oxidases in development.The vesicular monoamine transporter 2: an underexplored pharmacological target.Synthesis of Lobeline, Lobelane and their Analogues. A Review.Stereocontrolled synthesis and pharmacological evaluation of cis-2,6-diphenethyl-1-azabicyclo[2.2.2]octanes as lobelane analogues.Therapeutic advances in the management of Huntington's disease.Novel hypoglycemic dihydropyridones serendipitously discovered from O- versus C-alkylation in the synthesis of VMAT2 antagonists.Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2.Using the affective bias test to predict drug-induced negative affect: implications for drug safety.Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse.Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats.A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [3H]dopamine uptake at the vesicular monoamine transporter-2.Selection of sucrose concentration depends on the effort required to obtain it: studies using tetrabenazine, D1, D2, and D3 receptor antagonists.Altered expression of vesicular monoamine transporter 2 in epileptic patients and experimental rats.
P2860
Q24601233-98C71C81-BACF-4CCF-A554-E21E494AF284Q24654140-FCC35ADE-55FC-45F2-9609-57DCF7D72121Q27692599-63359918-E6F2-480D-86D0-7275692394B2Q28267531-8F403D44-5960-4C19-9B02-D5BADE15FD0AQ28271336-BB78CD1A-95E0-44D5-88D7-9AEC816654C7Q28550683-73A1A6DF-9D23-4D32-8AA7-6F50C3470E49Q30423703-8B7ECAC3-1DFA-4277-9870-F21201D6578BQ30462673-9D50812E-AE5C-4037-92D8-3A75A26165BEQ33729782-1D419B48-DBAA-422A-AEE8-FD96E3DB70B9Q33738102-F5815F44-1D6B-4B73-A0CC-B74F7EA03712Q34042123-07E36BD0-1519-4B07-A97A-D5F63A94BB21Q34823681-27FED988-5687-43D2-9804-532D7921F622Q35076611-B7DF5714-52BE-4537-B6D8-B3F89B9A769BQ36079830-B9F7B36F-3745-43A2-8F64-2CD7A079AEABQ36122702-415DD79A-7535-4446-86D6-5CA574AA8565Q36386171-FE659F38-CAFD-4E8E-87A4-E6C955CC33D2Q36719819-02AB861E-5B51-437A-B156-A6269B1D12B7Q37052442-BAA7957F-E9AA-4322-8F9F-3787DC7FE1BEQ37052450-F3246F15-22A3-40A0-9852-4CF7BDC8A084Q37081344-80F3525F-8C07-47C8-9954-892D092533EFQ37190441-A406F809-6076-4992-942A-5E094994E522Q37227997-C5AFBAD0-8A44-43BF-9182-21DD48C9F723Q37267145-5644E848-1A86-4C29-A371-94E411FEFAB7Q37396979-07C4E1AC-BED3-4593-9193-96170B7C0E5AQ37589110-E909AC49-B0D7-4A64-82C2-2268D0C28798Q37727587-A9105E46-C792-4B86-873A-99F1981E2C26Q38025300-A376D432-D253-4580-85ED-A026E0C950EFQ38176494-90335DA4-CA55-4A7D-B544-BBC838F309B7Q38267226-F640AE79-8869-4F43-B42D-A3B0FEFBE088Q38274875-875F9F9B-D90D-46F2-B452-C0FFF2C1A6D2Q38548033-2D18B907-99EA-4672-BD7D-1D1FE0D3A717Q39992795-74CADCF8-DDCC-423B-BFA0-3DA2C5D41F1FQ40664282-38553BEB-F078-4596-8890-6E6279FC44B6Q41203122-2FF89091-057A-4FE3-ABC1-3BC62DA1A183Q42098885-0FC3E6FA-D66B-4B49-85FC-F632C2292C57Q42864716-E652575A-C484-43FA-A24D-D3FDAA0013D8Q45288855-8D451920-733C-4EF0-9980-3795FFC526D8Q47387524-20A155D5-3CF6-4594-89AF-AB73239E632DQ47680336-DDE3A958-B014-49C5-B6A5-CD157AB59F42Q48121473-75CE409C-45B4-42CC-A1D2-FAACE115F8BC
P2860
Vesicular monoamine transporter 2: role as a novel target for drug development
description
2006 nî lūn-bûn
@nan
2006 թուականին հրատարակուած գիտական յօդուած
@hyw
2006 թվականին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Vesicular monoamine transporter 2: role as a novel target for drug development
@ast
Vesicular monoamine transporter 2: role as a novel target for drug development
@en
Vesicular monoamine transporter 2: role as a novel target for drug development
@nl
type
label
Vesicular monoamine transporter 2: role as a novel target for drug development
@ast
Vesicular monoamine transporter 2: role as a novel target for drug development
@en
Vesicular monoamine transporter 2: role as a novel target for drug development
@nl
prefLabel
Vesicular monoamine transporter 2: role as a novel target for drug development
@ast
Vesicular monoamine transporter 2: role as a novel target for drug development
@en
Vesicular monoamine transporter 2: role as a novel target for drug development
@nl
P2093
P2860
P356
P1433
P1476
Vesicular monoamine transporter 2: role as a novel target for drug development
@en
P2093
Guangrong Zheng
Linda P Dwoskin
Peter A Crooks
P2860
P2888
P304
P356
10.1208/AAPSJ080478
P407
P577
2006-01-01T00:00:00Z
P5875
P6179
1045528640